There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axcella Health (AXLA) and BioNTech SE (BNTX) with bullish sentiments.
Axcella Health (AXLA)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Axcella Health, with a price target of $19.00. The company’s shares closed last Monday at $5.23.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 8.6% and a 50.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
Axcella Health has an analyst consensus of Strong Buy, with a price target consensus of $15.33, representing a 195.4% upside. In a report issued on November 13, Chardan Capital also reiterated a Buy rating on the stock with a $16.00 price target.
See today’s analyst top recommended stocks >>
BioNTech SE (BNTX)
In a report issued on November 11, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on BioNTech SE, with a price target of $98.00. The company’s shares closed last Monday at $89.17.
According to TipRanks.com, Shu is ranked #4969 out of 7087 analysts.
Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $102.43, representing a 6.0% upside. In a report issued on November 11, Canaccord Genuity also maintained a Buy rating on the stock with a $115.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BNTX:
